Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

2.430 +0.160 (+7.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syros Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX)... 
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 89 companies hit new 52-week lows. Noteable 52-Week Lows: The company with the largest market cap to set a new 52-week low was Seagen (NASDAQ:SGEN).... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
21 Stocks Moving in Thursday's Pre-Market Session
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives sell over $20 million of 5 stocks... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Syros Pharmaceuticals (NASDAQ:SYRS 
Via Benzinga
Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
From Syros Pharmaceuticals
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Rivian Automotive (NASDAQ:RIVN) was the largest... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a... 
Via Benzinga
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Celyad Oncology (NASDAQ:CYAD) shares rose 22.75% to $4.37 during Friday's pre-market session. The company's market cap stands at $70.3 million. Biolase (... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! We're at the end of the week and it starts off with the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
From Syros Pharmaceuticals
Via Business Wire
Earnings Preview For Syros Pharmaceuticals
Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Friday, 2021-11-05. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For November 5, 2021
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEPC) is projected to report earnings for its third quarter. • Healthcare Trust (NYSE:HTA) is... 
Via Benzinga
Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer
From Syros Pharmaceuticals
Via Business Wire
Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Appointment of Conley Chee as Chief Commercial Officer
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609. Updated data demonstrated... 
Via Benzinga
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
From Syros Pharmaceuticals
Via Business Wire
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.